Cargando…
Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
The alkylating agent cyclophosphamide has been used in the treatment of multiple myeloma for over 60 years. At low doses, cyclophosphamide also has significant immunomodulatory activity, which can be used to modify the immunosuppressive tumor microenvironment in order to augment responses to existin...
Autores principales: | Swan, Dawn, Gurney, Mark, Krawczyk, Janusz, Ryan, Aideen E., O’Dwyer, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162079/ https://www.ncbi.nlm.nih.gov/pubmed/32309787 http://dx.doi.org/10.1097/HS9.0000000000000350 |
Ejemplares similares
-
Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
por: Swan, Dawn, et al.
Publicado: (2019) -
New developments in the treatment of multiple myeloma – clinical utility of daratumumab
por: McEllistrim, Cian, et al.
Publicado: (2017) -
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis
por: Naicker, Serika D, et al.
Publicado: (2021) -
Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022) -
Targeting the Pim kinases in multiple myeloma
por: Keane, N A, et al.
Publicado: (2015)